戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ascular repair upon FECH inhibition, without ocular toxicity.
2 ated with a variety of toxicities, including ocular toxicity.
3 al human ND4 in murine mitochondria posed no ocular toxicity.
4 h doses, or their combination does not cause ocular toxicity.
5 ug cessation, and the risks for irreversible ocular toxicity.
6 osition as well as for signs of irreversible ocular toxicity.
7  systemic drugs that have been implicated in ocular toxicity.
8  tamoxifen use, including the possibility of ocular toxicity.
9 en high dose of felodipine did not cause any ocular toxicity.
10 kg(-1), with no interstitial lung disease or ocular toxicity.
11  second cancers, and has few systemic and no ocular toxicities.
12  adhered well to the retina with no signs of ocular toxicities.
13 , and corneal changes as potential tamoxifen ocular toxicities.
14                    Participants with defined ocular toxicities 6 months before ICI treatment were exc
15             Despite numerous case reports of ocular toxicity, a pharmacoepidemiological study of thei
16 sicians should be aware of the potential for ocular toxicity among patients receiving the drug and sh
17 vitro assays to obtain initial estimates for ocular toxicities and thus minimize the need for the Dra
18                    In vivo bilateral topical ocular toxicity and antiviral efficacy were evaluated wi
19 uM SH-11037 was not associated with signs of ocular toxicity and did not interfere with retinal funct
20 ntation of monkeys with L or Z did not cause ocular toxicity and had no effect on biomarkers associat
21 astoma: they demonstrate low hematologic and ocular toxicity and no statistically significant influen
22 hat senolytic drugs do not carry significant ocular toxicity and provide further support for addition
23 uded the number and severity of systemic and ocular toxicities, and vision loss >/=15 ETDRS letters.
24     We reviewed the literature for described ocular toxicities associated with both approved and inve
25 to establish causality, data from reports of ocular toxicity associated with systemic cidofovir (Vist
26                       There were no signs of ocular toxicity at 1 year.
27 nged ocular drug retention and did not cause ocular toxicity at a dose of 150 mug of active agent.
28  clinical series, and clinical trial data on ocular toxicities attributed to tamoxifen.
29                               However, local ocular toxicities can be vision-threatening and long-ter
30        The 0.5% cidofovir exhibited the most ocular toxicity compared with FST-100, tobramycin/dexame
31 ow dose of Closantel and immediate referral, ocular toxicity could be resolved.
32                        All patients with EMB ocular toxicity developed symptoms between outpatient cl
33 s the potential risks of cardio-toxicity and ocular-toxicity exhibited by Hsp90beta-selective inhibit
34            After reviewing the literature on ocular toxicity following mistaken usage of Closantel in
35  inhibition of CatD as a principal driver of ocular toxicity for BACE1 inhibitors and more generally
36                     Assessing immune-related ocular toxicities from immune checkpoint inhibitors (ICI
37                                              Ocular toxicity has been described with numerous approve
38  cataracts, glaucoma, retinopathy, and other ocular toxicities have been reported following chemother
39 on on-target toxicities, cardio-toxicity and ocular-toxicity, have been attributed to inhibition of t
40 en withdrawn from development after inducing ocular toxicity in animal models, but the target mediati
41 ll tolerated without evidence of systemic or ocular toxicity in participants with NVAMD.
42 es did not affect IOP and showed no signs of ocular toxicity in rats for up to 6 months.
43 ent in cells with the probe is predictive of ocular toxicity in vivo.
44                                              Ocular toxicity is the most important potential EMB toxi
45                                              Ocular toxicity is uncommon in the current clinical sett
46 , but tolerability was affected by prevalent ocular toxicity, leading to a higher discontinuation rat
47                      Reports of drug-induced ocular toxicity must be well documented, and other cause
48          Because both of these agents induce ocular toxicity, novel inhibitors of autophagy with a be
49                           No AMG 386-related ocular toxicities occurred, and no treatment-related cli
50                            Subsequently, the ocular toxicities of six nonionic surfactants, Brij 700,
51 sent research was performed to ascertain the ocular toxicity of authentic lunar dust.
52 ome-based assay was developed for estimating ocular toxicity of surfactants.
53 stologic examination was performed to assess ocular toxicity of the delivery system.
54 and beta-toxin activity and demonstrates the ocular toxicity of these purified staphylococcal protein
55                                          The ocular toxicity of various compounds is typically determ
56  90 patients on intermittent therapy had EMB ocular toxicity (p = 0.05).
57 choroid may be the earliest manifestation of ocular toxicity, predating the development of clinically
58                                              Ocular toxicities previously associated with pan-Hsp90 i
59 ival, ocular survival, hematologic toxicity, ocular toxicity, second cancer development and electrore
60                                              Ocular toxicity studies revealed that intravitreal injec
61                                           An ocular toxicity study was performed in dogs older than 1
62  EBM administration was associated with less ocular toxicity than daily EMB administration in this pa
63 hemotherapy agents to consider the potential ocular toxicities that may result in their use.
64  NDNB1182 was found to avoid the cardio- and ocular-toxicity typical of Hsp90 pan-inhibitors (e.g. 17
65                                              Ocular toxicity was assessed and handled according to th
66                               No evidence of ocular toxicity was detected after focally delivered Car
67                                              Ocular toxicity was evaluated by clinical findings and e
68                                              Ocular toxicity was evaluated by clinical findings and e
69 lation study, no histopathologic evidence of ocular toxicity was observed at any dose.
70                              Importantly, no ocular toxicity was observed, indicating the safety of t
71                                    Transient ocular toxicities were observed after treatment, but mos
72                      No other indications of ocular toxicity were observed.
73 6%) on daily therapy were diagnosed with EMB ocular toxicity, whereas 0 of 90 patients on intermitten
74  sustained intravitreal drug release without ocular toxicity, which may be useful to inhibit unwanted
75 oncologists to be aware of the potential for ocular toxicity, with prompt recognition of symptoms tha